Ziprasidone hydrochloride Drugs, Importers, Informations, User, warnings, Reviews, Molecular Formula C21H21ClN4OS.HCl;C21H22Cl2N4OS, Molecular Weight 449.40, CAS Registry Number 138982-67-9, Side, Effects, Symptoms, Raw Material Exporters, Details, Drug Effectiveness, hydrochloride, fda, Information of Diseases, Drug, Details, Emergency, Interactions, api, Active Pharmaceutical Ingredients, Dosage, Taj Pharmaceuticals LTd.

Sitemap | Contact Us

Welcome To Taj Pharmaceuticals Ltd API

Ziprasidone-Hcl Taj API

India

Latin America/ Caribbean

Africa & Middle East

Asia

Russia

Europe

Ziprasidone Hcl Manufacturers in India Suppliers Ziprasidone Hcl Exporters Distributors Ziprasidone Hcl api active pharmaceuticals ingredients Ziprasidone Hcl manufacturers Side Effects bulk drugs raw material Ziprasidone Hcl companies Side Effects Importers Ziprasidone Hcl Ziprasidone Hcl Exporters Ziprasidone Hcl exporters FDA Ziprasidone Hcl DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Ziprasidone Hydrochloride manufacturing pharmaceutical drugs pharmaceutical intermediates Ziprasidone Hydrochloride pharmaceutical chemicals pharmaceutical raw materials Ziprasidone Hydrochloride active pharmaceutical ingredients Ziprasidone Hydrochloride committee active pharmaceutical ingredients manufacturer Ziprasidone Hydrochloride Active Pharmaceutical Ingredients manufacturer Ziprasidone Hydrochloride exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Ziprasidone Hcl, Ziprasidone Hcl manufacturer India, Ziprasidone Hcl product, Ziprasidone Hcl products, Api preparation, Certificate of Analysis API manufacturer product, Ziprasidone Hcl anti ulcer product, Certificate of Origin COA Ziprasidone Hcl COS Ziprasidone Hcl, pharmaceutical generic, pharmaceutical drug, medical, Ziprasidone Hcl pharma healthcare, pharma patents, contract MSDS manufacturing Trader Ziprasidone Hcl pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Ziprasidone Hcl expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Ziprasidone Hcl DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Ziprasidone Hcl ingredients, api, HIV Ziprasidone Hcl, tablets, capsules, syrup & protein Ziprasidone Hcl powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Ziprasidone Hcl gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Ziprasidone Hcl WHO, UKMHRA Approval

	PRODUCT LIST
	Home
	API >>>
	Pharmaceuticals API List
	Chemicals
	Manufacturing
	Product Development
	Product Search
	Agro Chemicals
	Custom Pharma Services
	Contact Us

taj pharma ltd. Ziprasidone-Hcl

HOME >> API >> API List 3 >> Ziprasidone Hcl >> Interaction

INTERACTION
Ziprasidone Hcl CAS Registry Number 138982-67-9

The Effect of Other Drugs on Ziprasidone

Carbamazepine - Carbamazepine is an inducer of CYP3A4; administration of 200 mg BID for 21 days resulted in a decrease of approximately 35% in the AUC of ziprasidone. This effect may be greater when higher doses of carbamazepine are administered.

Ketoconazole - Ketoconazole, a potent inhibitor of CYP3A4, at a dose of 400 mg QD for 5 days, increased the AUC and Cmax of ziprasidone by about 35-40%. Other inhibitors of CYP3A4 would be expected to have similar effects.

Cimetidine - Cimetidine at a dose of 800 mg QD for 2 days did not affect ziprasidone pharmacokinetics.

Antacid - The coadministration of 30 mL of Maalox® with ziprasidone did not affect the pharmacokinetics of ziprasidone.

In addition, population pharmacokinetic analysis of schizophrenic patients enrolled in controlled clinical trials has not revealed evidence of any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam.
Effect of Ziprasidone on Other Drugs

Lithium - Ziprasidone at a dose of 40 mg BID administered concomitantly with lithium at a dose of 450 mg BID for 7 days did not affect the steady-state level or renal clearance of lithium.

Oral Contraceptives - Ziprasidone at a dose of 20 mg BID did not affect the pharmacokinetics of concomitantly administered oral contraceptives, ethinyl estradiol (0.03 mg) and levonorgestrel (0.15 mg).

Dextromethorphan - Consistent with in vitro results, a study in normal healthy volunteers showed that ziprasidone did not alter the metabolism of dextromethorphan, a CYP2D6 model substrate, to its major metabolite, dextrorphan. There was no statistically significant change in the urinary dextromethorphan/dextrorphan ratio.

Information Associated with Product:

DRUG DESCRIPTION

DOSAGE

SIDE EFFECTS

PRECAUTIONS

INTERACTION >>

CONSUMER INFORMATION

PDF DOWNLOAD

WORD DOCUMENT


Product Enquiry	Product Quotation	Sample Request	Place Your Order

Taj Pharmaceuticals API Logo

Investor Relations Feedback Contact Worldwide Sitemap

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Limited products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.